Cardio Diagnostics Holdings, Inc. to List on Nasdaq Following Successful Business Combination with Mana Capital Acquisition Corp.
Summary
The combined company will operate under the name “Cardio Diagnostics Holdings, Inc.,” and will be led by Chief Executive Officer Meeshanthini (Meesha) Dogan, Ph.D., and the rest of its current management team. At the core of its cardiovascular solutions is a proprietary Integrated Genetic-Epigenetic Engine™ created at the University of Iowa by company founders Meesha Dogan, Ph.D., and Robert Philibert, MD, Ph.D. This technology enables the development of a series of tests for precision prevention, early detection, and assists in personalized treatment of major types of cardiovascular diseases and associated co-morbidities. Key healthcare stakeholders can successfully reduce the incidence of heart disease in America and across the globe, by radically reconsidering the current standard of cardiovascular care. This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 with respect to the business combination between Mana Capital and Cardio.
Classifications
AskAI Classifications
LabelsLinked Companies
